dyakonostrlin.blogspot.com
The 16-week trial gave 159 cancer patientss at 35 sites inthe U.S. and Argentinsa either one or three milligramk dosesof Ostraine, a selective androgen receptor The results show the one milligram dose gave patients 0.2 poundsa of lean body muscle. The three milligram dose increased muscle massby 2.9 and 3.3 "Approximately half of all cancer patients suffer from the devastatingb effects of cancer induced muscle Adrian Dobs, an investigator in the clinical trial and professoe of medicine and oncology at , said in a “Increasing lean body mass may improve patients' qualityh of life and even their response to cancer GTx (Nasdaq: GTXI) and (NYSE: MRK) are collaborating to develop Ostraine as part of a broaderr program for SARMs, a new class of drugzs with the potential to treayt musculoskeletal conditions.
Shares of Memphis-basedx GTx, a specialty pharmaceutical company, closed 32 centa higher Thursdayto $9.30 per share, up 3.44 percentt for the day.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment